Aro Biotherapeutics Announces $88M Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines
Aro Biotherapeutics Co. (developing tissue-targeted genetic medicines) announced the closing of an $88M Series A financing. Northpond Ventures and Cowen Healthcare Investments led the round, with participation from HealthCap, BVF Partners, and Ridgeback Capital. Existing investors, Johnson & Johnson Innovation – JJDC, BioMotiv, and Ionis Pharmaceuticals also participated in the round. Aro is developing a unique class of Centyrin-conjugated RNA therapies to efficiently and selectively target RNA medicines to the specific site of disease. The proceeds from the Series A will be used to advance the company’s lead therapeutic candidates into clinical development, with an initial focus in rare genetic and immune disorders.
- Drug Delivery
- Drug Discovery Tools
- Large Molecule
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.